hotspot -WSS

hotspot

author：entertainment 2025-09-14 14:39:36 - browse：4138

Multiple syringes in a vial -- Pharma coverage from STAT — Adobe

Roughly two million Americans are expected to receive a cancer diagnosis this year. Some members of this already vulnerable group will wind up facing what physician Andrew Schuman recently called “a tragedy happening in slow motion” — an ongoing, nationwide shortage of critical oncology drugs that routinely save or extend the lives of children and adults.

Speaking at a March 22 Senate hearing on drug shortages, Schuman, a head and neck surgeon at the U.S. Department of Veterans Affairs, described the agonizing decisions that doctors must make when critical medicines are in short supply. “Should our limited vials go to an older woman who was just diagnosed with lung cancer? To a young man who had already been successfully taking it for his testicular cancer? Or a baby with neuroblastoma?” he asked. “As a doctor who has devoted my life to fighting cancer, it is hard to express how horrible it is to face this kind of tragedy.”

The dilemmas caused by cancer drug shortages are unfortunately nothing new. In the past decade alone, eight of the 10 drugs most commonly used to treat acute lymphoblastic leukemia, the most common kind of childhood cancer type of leukemia, have been temporarily unavailable. The problem has been getting worse: Nationwide shortages of critical drugs increased nearly 30% in 2022, soaring to their highest level in nearly five years, according to a report released by the Senate Homeland Security and Governmental Affairs Committee for the hearing. Oncology drugs currently in short supply include methotrexate, which treats breast and soft tissue cancers; cisplatin, which treats testicular, ovarian, bladder, head and neck, lung, and cervical cancers; fluorouracil, which treats skin cancer; Pluvicto, for prostate cancer; and the injectable bacillus Calmette-Guérin, for bladder cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Amylyx ALS drug fails large clinical trial

WSS

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

First medicine developed to treat MASH expected to be approved soon

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

The Readout: Amylyx, Alumis, and Lundbeck drug updates

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Wegovy’s successful heart trial raises vital question about weight loss

explore

hotspot

focus

Wildfire smoke exposes gaps in outdoor worker protections

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The best solution to the drug shortages problem

DIEP, the 'gold standard' of breast reconstruction, is under threat

The drug industry has found itself all alone in Washington

Malaria cases in Florida and Texas: Here’s what you need to know

Why failed clinical trials don’t always spell doom for a new drug

What does generative AI mean for health care? We asked experts

The Readout: Amylyx, Alumis, and Lundbeck drug updates

explore

Novo Nordisk obesity pill bests Wegovy in early trial

CDC marks new Covid

Novo Nordisk obesity pill bests Wegovy in early trial

CDC marks new Covid

How to use technology to prevent future drug shortages

FDA panel issues narrow recommendation for Covid vaccine booster doses

explore

focus

leisure time

hotspot